What's new

Orphan designation: pelabresib monohydrate Treatment of myelofibrosis, 17/02/2025 Positive

Orphan designation: pelabresib monohydrate Treatment of myelofibrosis, 17/02/2025 Positive

Mar 12, 2025 - 17:05
 0
Orphan designation: pelabresib monohydrate Treatment of myelofibrosis, 17/02/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: Ornithine phenylacetate Treatment of acute liver failure, 20...

Next Article

Orphan designation: Seladelpar Treatment of primary biliary cholangitis, 20/02/2...

Related Posts

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 24, 2025  0

EMA Veterinary Innovation Day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 March 2025, 13:30 (CET) to 14 March 2025, 12:30 (CET)

EMA Veterinary Innovation Day, Online, European Medicin...

Feb 13, 2025  0

EMEA-001716-PIP07-22

EMEA-001716-PIP07-22

Feb 14, 2025  0